E85.81 Light chain (AL) amyloidosis

Name of the Condition

• Light chain (AL) amyloidosis
• ICD-10 Code: E85.81

Summary

Light chain (AL) amyloidosis is a disorder characterized by the abnormal deposition of light chain proteins (produced by plasma cells) in tissues and organs, disrupting their normal function. This buildup can affect multiple body systems, including the heart, kidneys, liver, and nervous system, leading to a range of clinical manifestations.

Causes

The condition is caused by abnormal plasma cells in the bone marrow that produce excessive light chain proteins, which misfold and deposit as amyloid fibrils in organs. It is often associated with plasma cell disorders, such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).

Risk Factors

• Monoclonal gammopathy of undetermined significance (MGUS).
• Multiple myeloma or other plasma cell disorders.
• Age (more common in older adults).
• Family history of plasma cell disorders.
• Prior exposure to certain medications or environmental factors (rare).

Symptoms

• Fatigue and unexplained weight loss.
• Swelling in the ankles, legs, or abdomen (edema).
• Shortness of breath or heart palpitations (cardiac involvement).
• Kidney dysfunction or proteinuria.
• Numbness or tingling in the hands or feet (peripheral neuropathy).
• Gastrointestinal symptoms like diarrhea or constipation.
• Liver enlargement or abnormal liver function tests.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and tissue biopsy. Biopsy samples are stained with Congo red to confirm amyloid deposits, and immunohistochemistry or mass spectrometry may identify light chain proteins. Additional tests include serum and urine immunofixation electrophoresis to detect monoclonal proteins, and imaging studies (e.g., echocardiogram) to assess organ involvement.

Treatment Options

Treatment focuses on reducing the production of abnormal light chains and managing organ damage. Options may include chemotherapy, targeted therapies (e.g., proteasome inhibitors), stem cell transplantation, or supportive care for organ dysfunction. Treatment plans are tailored to the extent of organ involvement and overall health.

Prognosis and Follow-Up

Prognosis varies based on organ involvement and response to treatment. Early diagnosis and intervention can improve outcomes, but severe cardiac or renal involvement may worsen prognosis. Follow-up includes regular monitoring of organ function, protein levels, and treatment response, with adjustments to therapy as needed.

Complications

• Heart failure or arrhythmias (cardiac involvement).
• Kidney failure requiring dialysis.
• Peripheral neuropathy or autonomic dysfunction.
• Gastrointestinal bleeding or malabsorption.
• Liver failure in severe cases.

Lifestyle & Prevention

• Maintain a balanced diet and manage fluid intake (especially with kidney or heart involvement).
• Avoid medications that may worsen organ function (e.g., nephrotoxic drugs).
• Engage in regular, moderate exercise as tolerated to support overall health.
• Monitor for symptoms and attend follow-up appointments to address complications early.

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained swelling, shortness of breath, or other symptoms of organ dysfunction. Prompt evaluation is critical for early diagnosis and treatment, especially if you have a history of plasma cell disorders.

Tips for Medical Coders

Document the specific organ systems involved (e.g., cardiac, renal) and any associated plasma cell disorders, as these details support accurate coding. Ensure biopsy results confirming amyloid deposits and light chain protein identification are clearly documented. Code E85.81 is specific to light chain (AL) amyloidosis and should not be used for other amyloidosis subtypes.